Preexisting Antibodies to an F(ab′)2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment

Article English OPEN
Ruppel, Jane; Brady, Ann; Elliott, Rebecca; Leddy, Cecilia; Palencia, Marco; Coleman, Daniel; Couch, Jessica A.; Wakshull, Eric;
  • Publisher: Hindawi Publishing Corporation
  • Journal: Journal of Immunology Research,volume 2,016 (issn: 2314-8861, eissn: 2314-7156)
  • Related identifiers: pmc: PMC4927981, doi: 10.1155/2016/2921758
  • Subject: Research Article | Article Subject

Anti-therapeutic antibodies (ATAs) may impact drug exposure and activity and induce immune complex mediated toxicity; therefore the accurate measurement of ATA is important for the analysis of drug safety and efficacy. Preexisting ATAs to the hinge region of anti-Delta ... View more
  • References (28)
    28 references, page 1 of 3

    Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A., Rutgeerts, P.. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New England Journal of Medicine. 2003; 348 (7): 601-608

    U.S. Department of Health and Human Services, null, Food and Drug Administration, null, CDER, null, CBER, null. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products,. 2014

    European Medicines Agency. Committee for Medicinal Products for Human Use, null. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc. Ref.. 2007 (EMEA/CHMP/BMWP/14327/2006)

    European Medicines Agency, null, Committee for Medicinal Products for Human Use, null. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins intended for in-vivo clinical use. Doc. Ref.. 2012 (EMA/CHMP/BMWP/86289/2010)

    Pastuskovas, C. V., Mallet, W., Clark, S., Kenrick, M., Majidy, M., Schweiger, M., Van Hoy, M., Tsai, S. P., Bennett, G., Shen, B.-Q., Ross, S., Fielder, P., Khawli, L., Tibbitts, J.. Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metabolism and Disposition. 2010; 38 (12): 2309-2319

    Fox, J. A., Hotaling, T. E., Struble, C., Ruppel, J., Bates, D. J., Schoenhoff, M. B.. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics. 1996; 279 (2): 1000-1008

    Brezski, R. J., Luongo, J. L., Petrone, D., Ryan, M. H., Zhong, D., Tam, S. H., Schmidt, A. P., Kruszynski, M., Whitaker, B. P., Knight, D. M., Jordan, R. E.. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. Journal of Immunology. 2008; 181 (5): 3183-3192

    Keiserman, M., Codreanu, C., Handa, R., Xibillé-Friedmann, D., Mysler, E., Briceño, F., Akar, S.. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Review of Clinical Immunology. 2014; 10 (8): 1049-1057

    Rao, P. K., Dorsch, M., Chickering, T., Zheng, G., Jiang, C., Goodearl, A., Kadesch, T., McCarthy, S.. Isolation and characterization of the notch ligand Delta4. Experimental Cell Research. 2000; 260 (2): 379-386

    Shutter, J. R., Scully, S., Fan, W., Richards, W. G., Kitajewski, J., Deblandre, G. A., Kintner, C. R., Stark, K. L.. D114, a novel Notch ligand expressed in arterial endothelium. Genes and Development. 2000; 14 (11): 1313-1318

  • Similar Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark